CN105168202A - Inhalational compound anesthesia maintenance agent - Google Patents
Inhalational compound anesthesia maintenance agent Download PDFInfo
- Publication number
- CN105168202A CN105168202A CN201510648398.4A CN201510648398A CN105168202A CN 105168202 A CN105168202 A CN 105168202A CN 201510648398 A CN201510648398 A CN 201510648398A CN 105168202 A CN105168202 A CN 105168202A
- Authority
- CN
- China
- Prior art keywords
- content
- anesthesia
- sevoflurane
- halothane
- wogonin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010002091 Anaesthesia Diseases 0.000 title claims abstract description 37
- 230000037005 anaesthesia Effects 0.000 title claims abstract description 37
- 238000012423 maintenance Methods 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960003132 halothane Drugs 0.000 claims abstract description 19
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960002078 sevoflurane Drugs 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 17
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 17
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 17
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 17
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 17
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 17
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 17
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 17
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 17
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 17
- 229940041616 menthol Drugs 0.000 claims abstract description 17
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 abstract description 9
- 206010028813 Nausea Diseases 0.000 abstract description 4
- 230000008693 nausea Effects 0.000 abstract description 4
- 206010019233 Headaches Diseases 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 231100000869 headache Toxicity 0.000 abstract description 3
- 230000004224 protection Effects 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 3
- 230000029865 regulation of blood pressure Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 208000002033 Myoclonus Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 238000002695 general anesthesia Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 229960001730 nitrous oxide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供一种吸入式复合麻醉维持剂，包括氟烷、七氟烷、薄荷脑、绿原酸、汉黄芩素和乙醇，具体配比为氟烷含量0.5％ˉ1％，七氟烷含量0.4％ˉ0.8％，薄荷脑含量0.1％ˉ0.3％，绿原酸含量0.2％ˉ0.6％，汉黄芩素含量0.1％ˉ0.4％，乙醇含量0.4％ˉ1％。本发明不但具有良好的麻醉维持作用，还具有抗炎、调节血压以及保护心血管的功效，减少了麻醉复苏期间部分病人出现肌阵挛、恶心、头痛等不良反应。The invention provides an inhalation compound anesthesia maintenance agent, which comprises halothane, sevoflurane, menthol, chlorogenic acid, wogonin and ethanol, and the specific proportion is 0.5%-1% of halothane content, 0.4% of sevoflurane content %ˉ0.8%, menthol content 0.1%ˉ0.3%, chlorogenic acid content 0.2%ˉ0.6%, wogonin content 0.1%ˉ0.4%, ethanol content 0.4%ˉ1%. The invention not only has a good anesthesia maintenance effect, but also has anti-inflammation, blood pressure regulation and cardiovascular protection effects, and reduces adverse reactions such as myoclonus, nausea and headache in some patients during anesthesia recovery.
Description
技术领域technical field
本发明涉及一种吸入式麻醉剂，具体为一种吸入式复合麻醉维持剂。The invention relates to an inhalation anesthetic, in particular to an inhalation compound anesthesia maintenance agent.
背景技术Background technique
吸入式麻醉作为一种全身麻醉施用，可产生呼吸道损伤、呼吸抑制、心律失常等不良副作用。现在常用的吸入式麻醉药为乙醚、氟烷、七氟烷、氧化亚氮等。乙醚具有毒性低、安全范围较大的优点，但是对呼吸器官具有刺激作用，遇明火极易产生爆炸。氟烷、七氟烷虽然具有性稳定、不燃不爆、麻醉作用强等优点，但易出现血压降低、心率失常等副作用。氧化亚氮诱导期短、镇痛效果好，但肌松不完全，全麻效能弱。现常用吸入式麻醉药物在麻醉复苏期间，易出现恶心、呕吐及头痛等现象。Inhalational anesthesia, administered as a form of general anesthesia, can produce adverse side effects such as airway damage, respiratory depression, and cardiac arrhythmia. Commonly used inhalational anesthetics are ether, halothane, sevoflurane, and nitrous oxide. Ethyl ether has the advantages of low toxicity and a large safety range, but it has a stimulating effect on the respiratory organs, and it is very easy to explode when exposed to an open flame. Although halothane and sevoflurane have the advantages of stable sex, non-flammable and non-explosive, and strong anesthetic effect, they are prone to side effects such as blood pressure drop and cardiac arrhythmia. The induction period of nitrous oxide is short, and the analgesic effect is good, but the muscle relaxation is not complete, and the general anesthesia effect is weak. Commonly used inhaled anesthetics are prone to nausea, vomiting and headache during recovery from anesthesia.
发明内容Contents of the invention
针对现有麻醉存在的问题，结合麻醉临床的需要，研发一种吸入式复合麻醉维持剂。本发明具有良好的麻醉效果，同时将各单药的副作用降低，克服普通吸入麻醉产生的恶心、呕吐、镇痛效果差等问题。Aiming at the problems existing in the existing anesthesia, combined with the clinical needs of anesthesia, an inhaled compound anesthesia maintenance agent was developed. The invention has good anesthesia effect, reduces the side effects of each single drug, and overcomes the problems of nausea, vomiting and poor analgesic effect caused by common inhalation anesthesia.
本发明提供了一种吸入式复合麻醉维持剂，包括氟烷、七氟烷、薄荷脑、绿原酸、汉黄芩素和乙醇。The invention provides an inhaled compound anesthesia maintenance agent, which comprises halothane, sevoflurane, menthol, chlorogenic acid, wogonin and ethanol.
所述的吸入式复合麻醉维持剂中氟烷含量为0.5％-1％，七氟烷含量为0.4％-0.8％，薄荷脑含量为0.1％-0.3％，绿原酸含量为0.2％-0.6％，汉黄芩素含量为0.1％-0.4％，乙醇含量为0.4％-1％。The content of halothane in the inhaled compound anesthesia maintenance agent is 0.5%-1%, the content of sevoflurane is 0.4%-0.8%, the content of menthol is 0.1%-0.3%, and the content of chlorogenic acid is 0.2%-0.6%. %, the content of wogonin is 0.1%-0.4%, and the content of ethanol is 0.4%-1%.
本发明的制备过程为：将薄荷脑、绿原酸、汉黄芩素按照配方剂量，加入到乙醇中，在室温下溶解，然后将氟烷、七氟烷加入到溶解的混合液中，将复合麻醉维持剂封存。The preparation process of the present invention is as follows: add menthol, chlorogenic acid, and wogonin into ethanol according to the formula dosage, dissolve at room temperature, then add halothane and sevoflurane into the dissolved mixed solution, and compound Anesthesia maintenance agent storage.
本发明的使用方法为：本发明用于全身麻醉中的麻醉维持期，采用半闭合式或闭合式麻醉机给药。成人用药量为0.5-0.25mL/(Kg·h)，儿童用药量为0.8-0.32mL/(Kg·h)。The method of use of the present invention is: the present invention is used in the anesthesia maintenance period in general anesthesia, and a semi-closed or closed anesthesia machine is used for administration. The dosage for adults is 0.5-0.25mL/(Kg·h), and the dosage for children is 0.8-0.32mL/(Kg·h).
本发明的有益效果：本发明以氟烷、七氟烷为基础药物，辅助药物为具有消炎、止痛效果的薄荷脑，调控血压、保护心血管功效的绿原酸，抗炎及抗痉挛功效的汉黄芩素；本发明不但具有良好的麻醉维持作用，还具有抗炎、调节血压以及保护心血管的功效，减少了麻醉复苏期间部分病人出现肌阵挛、恶心、头痛等不良反应。Beneficial effects of the present invention: the present invention uses halothane and sevoflurane as basic medicines, and auxiliary medicines are menthol with anti-inflammatory and analgesic effects, chlorogenic acid for blood pressure regulation and cardiovascular protection, anti-inflammatory and anti-spasmodic effects Wogonin: The present invention not only has good anesthesia maintenance effect, but also has anti-inflammation, blood pressure regulation and cardiovascular protection effects, and reduces adverse reactions such as myoclonus, nausea and headache in some patients during anesthesia recovery.
具体实施方式Detailed ways
实施例1：Example 1:
一种吸入式复合麻醉维持剂，包括氟烷、七氟烷、薄荷脑、绿原酸、汉黄芩素和乙醇。An inhaled compound anesthesia maintenance agent, including halothane, sevoflurane, menthol, chlorogenic acid, wogonin and ethanol.
所述复合麻醉维持剂的具体含量配比为：氟烷0.5％，七氟烷0.8％，薄荷脑0.15％，绿原酸0.35％，汉黄芩素0.2％，乙醇0.5％。The specific content ratio of the compound anesthesia maintenance agent is: 0.5% of halothane, 0.8% of sevoflurane, 0.15% of menthol, 0.35% of chlorogenic acid, 0.2% of wogonin and 0.5% of ethanol.
将薄荷脑、绿原酸、汉黄芩素按照配方剂量，加入到乙醇中，在室温下溶解，然后将氟烷、七氟烷加入到溶解的混合液中，将复合麻醉维持剂封存。Add menthol, chlorogenic acid, and wogonin to ethanol according to the prescribed dosage, dissolve at room temperature, then add halothane and sevoflurane to the dissolved mixture, and seal up the compound anesthesia maintenance agent.
本发明用于全身麻醉中的麻醉维持期，采用半闭合式或闭合式麻醉机给药。成人用药量为0.5-0.25mL/(Kg·h)，儿童用药量为0.8-0.32mL/(Kg·h)。The present invention is used in the anesthesia maintenance period in general anesthesia, and adopts a semi-closed or closed anesthesia machine for administration. The dosage for adults is 0.5-0.25mL/(Kg·h), and the dosage for children is 0.8-0.32mL/(Kg·h).
实施例2：Example 2:
一种吸入式复合麻醉维持剂，包括氟烷、七氟烷、薄荷脑、绿原酸、汉黄芩素和乙醇。An inhaled compound anesthesia maintenance agent, including halothane, sevoflurane, menthol, chlorogenic acid, wogonin and ethanol.
所述复合麻醉维持剂的具体含量配比为：氟烷0.75％，七氟烷0.6％，薄荷脑0.3％，绿原酸0.5％，汉黄芩素0.3％，乙醇0.8％。The specific content ratio of the compound anesthesia maintenance agent is: 0.75% of halothane, 0.6% of sevoflurane, 0.3% of menthol, 0.5% of chlorogenic acid, 0.3% of wogonin and 0.8% of ethanol.
将薄荷脑、绿原酸、汉黄芩素按照配方剂量，加入到乙醇中，在室温下溶解，然后将氟烷、七氟烷加入到溶解的混合液中，将复合麻醉维持剂封存。Add menthol, chlorogenic acid, and wogonin to ethanol according to the prescribed dosage, dissolve at room temperature, then add halothane and sevoflurane to the dissolved mixture, and seal up the compound anesthesia maintenance agent.
本发明用于全身麻醉中的麻醉维持期，采用半闭合式或闭合式麻醉机给药。成人用药量为0.5-0.25mL/(Kg·h)，儿童用药量为0.8-0.32mL/(Kg·h)。The present invention is used in the anesthesia maintenance period in general anesthesia, and adopts a semi-closed or closed anesthesia machine for administration. The dosage for adults is 0.5-0.25mL/(Kg·h), and the dosage for children is 0.8-0.32mL/(Kg·h).
实施例3：Example 3:
一种吸入式复合麻醉维持剂，包括氟烷、七氟烷、薄荷脑、绿原酸、汉黄芩素和乙醇。An inhaled compound anesthesia maintenance agent, including halothane, sevoflurane, menthol, chlorogenic acid, wogonin and ethanol.
所述复合麻醉维持剂的具体含量配比为：氟烷1％，七氟烷0.4％，薄荷脑0.2％，绿原酸0.4％，汉黄芩素0.25％，乙醇0.6％。The specific content ratio of the compound anesthesia maintenance agent is: 1% of halothane, 0.4% of sevoflurane, 0.2% of menthol, 0.4% of chlorogenic acid, 0.25% of wogonin, and 0.6% of ethanol.
将薄荷脑、绿原酸、汉黄芩素按照配方剂量，加入到乙醇中，在室温下溶解，然后将氟烷、七氟烷加入到溶解的混合液中，将复合麻醉维持剂封存。Add menthol, chlorogenic acid, and wogonin to ethanol according to the prescribed dosage, dissolve at room temperature, then add halothane and sevoflurane to the dissolved mixture, and seal up the compound anesthesia maintenance agent.
本发明用于全身麻醉中的麻醉维持期，采用半闭合式或闭合式麻醉机给药。成人用药量为0.5-0.25mL/(Kg·h)，儿童用药量为0.8-0.32mL/(Kg·h)。The present invention is used in the anesthesia maintenance period in general anesthesia, and adopts a semi-closed or closed anesthesia machine for administration. The dosage for adults is 0.5-0.25mL/(Kg·h), and the dosage for children is 0.8-0.32mL/(Kg·h).
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510648398.4A CN105168202A (en) | 2015-10-09 | 2015-10-09 | Inhalational compound anesthesia maintenance agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510648398.4A CN105168202A (en) | 2015-10-09 | 2015-10-09 | Inhalational compound anesthesia maintenance agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105168202A true CN105168202A (en) | 2015-12-23 |
Family
ID=54890977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510648398.4A Pending CN105168202A (en) | 2015-10-09 | 2015-10-09 | Inhalational compound anesthesia maintenance agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105168202A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88100564A (en) * | 1987-02-02 | 1988-08-17 | Boc公司 | Anesthetic compositions and methods of use thereof |
| CN102973722A (en) * | 2012-11-28 | 2013-03-20 | 赵作君 | Novel anesthetic |
| CN104619319A (en) * | 2012-07-10 | 2015-05-13 | 加利福尼亚大学董事会 | method of inducing anesthesia |
| CN104623084A (en) * | 2015-02-06 | 2015-05-20 | 孟建 | Inhalational compound anaesthetic agent |
-
2015
- 2015-10-09 CN CN201510648398.4A patent/CN105168202A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN88100564A (en) * | 1987-02-02 | 1988-08-17 | Boc公司 | Anesthetic compositions and methods of use thereof |
| CN104619319A (en) * | 2012-07-10 | 2015-05-13 | 加利福尼亚大学董事会 | method of inducing anesthesia |
| CN102973722A (en) * | 2012-11-28 | 2013-03-20 | 赵作君 | Novel anesthetic |
| CN104623084A (en) * | 2015-02-06 | 2015-05-20 | 孟建 | Inhalational compound anaesthetic agent |
Non-Patent Citations (3)
| Title |
|---|
| M.R.J.SURY 等: "A comparison of the recovery characteristics of sevoflurane and halothane in children", 《ANAESTHESIA》 * |
| 刘中景 等: "《中西医结合营养学》", 31 August 2013, 科学技术文献出版社 * |
| 刘斌: "《中药成分体内代谢与分析》", 31 August 2011, 中国中医药出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BLUMENFELD et al. | Sodium gamma-hydroxybutyric acid: a new anesthetic adjuvant | |
| JP2022136154A (en) | Composition for treating schizophrenia | |
| Tobias | Inhalational anesthesia: basic pharmacology, end organ effects, and applications in the treatment of status asthmaticus | |
| CN106806359A (en) | A solution preparation for nebulization inhalation of andrographolide or its medicinal salt and its preparation method | |
| CN105287846A (en) | Application of Shanhaidan Yujin injection in atomizing inhalation, spray bottle aerosol and rectal administration and method | |
| CN106667974A (en) | Preparation method of terbutaline sulfate solution for inhalation | |
| CN105311081A (en) | Application of Shanhaidan chrysanthemum indicum injection in aerosol inhalation, spray bottle aerial fog and rectal administration and method | |
| CN106138015A (en) | Propofol self-micro-emulsifying composition | |
| CN104606205A (en) | Pharmaceutical composition of olodaterol and budesonide and use of pharmaceutical composition | |
| CN105168202A (en) | Inhalational compound anesthesia maintenance agent | |
| JP2011500731A5 (en) | ||
| CN102973722B (en) | Novel anesthetic | |
| RU2012116226A (en) | Broncholytic agent based on prostaglandin | |
| CN105456234A (en) | Novel propellant asarone inhalation aerosol and preparation method thereof | |
| CN112999204A (en) | Shuanghuanglian aerosol inhalation solution preparation and preparation method thereof | |
| WO2019091082A1 (en) | Solution preparation for aerosol inhalation of carbocisteine, and preparation method therefor | |
| CN114344380A (en) | Asthma-relieving aerosol inhalation solution preparation and preparation method thereof | |
| CN107334754B (en) | Qingkailing solution preparation for aerosol inhalation and preparation method thereof | |
| Frizzi | Sevoflurane as a therapy for acute chlorine gas exposure in an austere healthcare environment: a case report | |
| CN104800396A (en) | Anesthetic and preparation method and use method thereof | |
| Vandse et al. | Anesthesia & Clinical | |
| CN104887689A (en) | Medicine composition containing ambroxol hydrochloride and fructose | |
| Wang et al. | Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patients: A Randomized Clinical Trial | |
| Kashav et al. | TIVA versus Inhalational Agents for Pediatric Cardiac Intensive. | |
| CN102206204B (en) | Benzimidazole compound and medicinal application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151223 |